MediPharm Labs (TSE:LABS) Director Christopher David Taves Sells 176,786 Shares of Stock

MediPharm Labs Corp. (TSE:LABS) Director Christopher David Taves sold 176,786 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of C$0.08, for a total value of C$14,142.88. Following the completion of the transaction, the director owned 2,847,939 shares in the company, valued at C$227,835.12. This represents a 5.84% decrease in their position.

MediPharm Labs Stock Up 7.1%

LABS stock opened at C$0.08 on Friday. MediPharm Labs Corp. has a twelve month low of C$0.06 and a twelve month high of C$0.10. The company has a quick ratio of 3.10, a current ratio of 3.02 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average is C$0.08 and its 200-day moving average is C$0.07. The firm has a market capitalization of C$31.86 million, a PE ratio of -3.75 and a beta of -0.61.

MediPharm Labs Company Profile

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products produced in a GMP-certified facility with ISO-standard clean rooms. MediPharm has invested in an expert research-driven team, state-of-the-art technology, advanced purification methodologies, and purpose-built facilities to deliver pure, trusted, precision-dosed cannabinoid products for domestic and international markets.